CELZ Moves to 80% Control of BioDefense in Related-Party Transaction
CELZ sits 61% above its 52-week low of $0.62.
Summary
CELZ acquired 4 million BioDefense shares for $200,000 cash and 1 million CELZ shares, raising its stake to 80% in a related-party deal with an entity controlled by CEO Timothy Warbington.
Key Events · M&A and Partnerships · CELZ
-
Controlling Stake Acquired
CELZ purchased 4,000,000 BioDefense shares from Creative Acquisition Corp., increasing its ownership from 60% to 80% of BioDefense's outstanding common stock.
-
Related-Party Consideration
Purchase price was $200,000 cash plus 1,000,000 newly issued CELZ shares. Seller Creative Acquisition Corp. is controlled by CELZ CEO Timothy Warbington, who indirectly owns all of its shares.
-
Equity Issuance
The 1,000,000 CELZ shares were issued in a private placement under Section 4(a)(2) of the Securities Act, adding to the company's outstanding share count.
-
Ownership Structure
After the transaction, CELZ owns 16,000,000 BioDefense shares (80%) and Creative Acquisition Corp. retains 4,000,000 shares (20%).
Analysis · CELZ · Life Sciences
To lift its BioDefense ownership from 60% to 80%, CELZ paid $200,000 in cash plus 1 million of its own shares. The seller, Creative Acquisition Corp., is controlled by CELZ's own CEO Timothy Warbington, making this a related-party transaction that consolidates control of BioDefense under CELZ while issuing new equity to an entity tied to its chief executive.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CELZ was trading at $1.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.8M. The 52-week trading range was $0.62 to $6.25. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.